Study Overview: This study aims to find out if a special scan called PYLARIFY PET/CT or PYLARIFY PET/MRI can safely and accurately see if prostate cancer is spreading beyond the prostate gland in men who have a type of prostate cancer called favorable intermediate risk (FIR) prostate cancer. Participants will get a single injection of PYLARIFY, followed by a full-body scan 1-2 hours later. If the scan shows cancer outside the prostate, more tests or treatments may be recommended.

• Duration: Participants will be monitored for up to 12 months to track treatment and PSA blood test results.
• Eligibility: Must be 18+, able to sign a form, and have confirmed FIR prostate cancer.
• Exclusions: Previous prostate cancer treatments or allergies to PYLARIFY ingredients will disqualify participation.

Note: PYLARIFY helps doctors see cancer activity, and this study checks if it works well for patients with this type of prostate cancer. Participants' health will be followed for a year to gather important data.